Lymphoproliferative Disorders  >>  Mekinist (trametinib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Mekinist (trametinib) / Novartis, BeiGene
NCT02140840: UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib

Withdrawn
2
0
US
Trametinib, Mekinist, TMTB, JTP-74057, JTP-78296, JTP-75303
University of Arkansas
Multiple Myeloma
04/16
04/16
NCT01476137: A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers

Completed
1/2
335
US
GSK1120212, GSK2110183
GlaxoSmithKline
Cancer
03/13
03/13

Download Options